Our Pomegranate formulation delivers a concentrated source of polyphenols and ellagitannins, precursors to Urolithin A — a compound studied for its role in mitochondrial function and cellular renewal (mitophagy). Rich in natural antioxidants, this bottle is designed to support research into oxidative stress defense, metabolic resilience, and longevity pathways. As with all products in our Longevity line, this is intended strictly for laboratory and research applications.
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
Our Pomegranate formulation delivers a concentrated source of polyphenols and ellagitannins, precursors to Urolithin A — a compound studied for its role in mitochondrial function and cellular renewal (mitophagy). Rich in natural antioxidants, this bottle is designed to support research into oxidative stress defense, metabolic resilience, and longevity pathways. As with all products in our Longevity line, this is intended strictly for laboratory and research applications.
For research use only. Not for human consumption. Not evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease.
| Type | Synthetic compound |
|---|---|
| Category | Research Compound |
| Purity | ≥99% |
| Form | Lyophilized powder |
-20°C · 24+ months
2–8°C · ~30 days
Third-party tested for purity and quality.
| Variant | GLP3-RT 10mg |
|---|---|
| Lot # | REF0001 |
| Labeled | 20mg |
| Actual | 22.61mg |
| Tested | APR 15, 2026 |
Coming soon
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
Triple–Hormone-Receptor Agonist GLP-3 (RT) for Obesity — A Phase 2 Trial
2023
DOI: 10.1056/NEJMoa2301972
· Jastreboff AM, et al.
on orders over $200
plain and unbranded packaging
256-bit SSL
Not a researcher? Exit
